JP2015530358A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015530358A5 JP2015530358A5 JP2015521549A JP2015521549A JP2015530358A5 JP 2015530358 A5 JP2015530358 A5 JP 2015530358A5 JP 2015521549 A JP2015521549 A JP 2015521549A JP 2015521549 A JP2015521549 A JP 2015521549A JP 2015530358 A5 JP2015530358 A5 JP 2015530358A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- active ingredient
- conjugate according
- composition
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 239000004480 active ingredient Substances 0.000 claims 32
- 210000004027 cell Anatomy 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 13
- 239000002872 contrast media Substances 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 8
- 210000003470 mitochondria Anatomy 0.000 claims 6
- 230000002438 mitochondrial effect Effects 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000035699 permeability Effects 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000000805 cytoplasm Anatomy 0.000 claims 3
- 230000001086 cytosolic effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 235000013402 health food Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- -1 antibody Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- GPRSOIDYHMXAGW-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopentanecarboxylic acid iron Chemical group [CH-]1[CH-][CH-][C-]([CH-]1)C(=O)O.[CH-]1C=CC=C1.[Fe] GPRSOIDYHMXAGW-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2012-0075444 | 2012-07-11 | ||
| KR20120075444 | 2012-07-11 | ||
| KR10-2012-0104173 | 2012-09-19 | ||
| KR20120104173 | 2012-09-19 | ||
| KR10-2012-0109207 | 2012-09-28 | ||
| KR20120109207 | 2012-09-28 | ||
| KR20130017046 | 2013-02-18 | ||
| KR10-2013-0017046 | 2013-02-18 | ||
| KR10-2013-0043635 | 2013-04-19 | ||
| KR20130043635 | 2013-04-19 | ||
| PCT/KR2013/006218 WO2014010971A1 (ko) | 2012-07-11 | 2013-07-11 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015530358A JP2015530358A (ja) | 2015-10-15 |
| JP2015530358A5 true JP2015530358A5 (enExample) | 2016-09-01 |
| JP6272853B2 JP6272853B2 (ja) | 2018-01-31 |
Family
ID=49916328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521549A Active JP6272853B2 (ja) | 2012-07-11 | 2013-07-11 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10967000B2 (enExample) |
| EP (1) | EP2873678B8 (enExample) |
| JP (1) | JP6272853B2 (enExample) |
| KR (1) | KR101799904B1 (enExample) |
| CN (1) | CN104822698B (enExample) |
| ES (1) | ES2981865T3 (enExample) |
| WO (1) | WO2014010971A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013169060A1 (ko) | 2012-05-11 | 2013-11-14 | 주식회사 카엘젬백스 | 패혈증 예방 또는 치료용 조성물 |
| ES2691070T3 (es) | 2012-05-11 | 2018-11-23 | Kael-Gemvax Co.,Ltd | Péptidos antiinflamatorios y composición que comprende los mismos |
| TWI678374B (zh) * | 2012-09-19 | 2019-12-01 | 韓商傑姆維克斯＆凱爾有限公司 | 穿膜胜肽以及包含該胜肽之共軛物及組成物(三) |
| US9631184B2 (en) | 2012-09-19 | 2017-04-25 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| TWI616531B (zh) | 2012-09-19 | 2018-03-01 | 傑姆維克斯＆凱爾有限公司 | 穿膜胜肽以及包含該胜肽之共軛物及組成物（二） |
| KR102258864B1 (ko) | 2013-04-19 | 2021-06-01 | 주식회사 젬백스앤카엘 | 허혈성 손상 치료 및 예방용 조성물 |
| RU2677277C2 (ru) | 2013-06-07 | 2019-01-16 | Джемвакс Энд Каэл Ко., Лтд. | Биологические маркеры, которые могут быть использованы в иммунотерапии рака |
| TWI539960B (zh) | 2013-06-21 | 2016-07-01 | 凱爾傑姆維克斯有限公司 | 激素分泌調節劑、包括其的組成物以及其用途 |
| CA2926183C (en) | 2013-10-23 | 2018-07-03 | Gemvax & Kael Co., Ltd. | Composition for treating and preventing benign prostatic hyperplasia |
| EP3072519B1 (en) | 2013-11-22 | 2020-08-19 | Gemvax & Kael Co., Ltd. | Peptide having angiogenesis inhibitory activity and composition containing same |
| ES2809251T3 (es) | 2013-12-17 | 2021-03-03 | Gemvax & Kael Co Ltd | Composición para tratar cáncer de próstata |
| JP6420459B2 (ja) | 2014-04-11 | 2018-11-07 | ジェムバックス アンド カエル カンパニー，リミティド | 線維症抑制活性を有するペプチド及びこれを含む組成物 |
| US10662223B2 (en) | 2014-04-30 | 2020-05-26 | Gemvax & Kael Co., Ltd. | Composition for organ, tissue, or cell transplantation, kit, and transplantation method |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| KR102636129B1 (ko) | 2015-02-27 | 2024-02-14 | 주식회사 젬백스앤카엘 | 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물 |
| WO2016190660A1 (ko) | 2015-05-26 | 2016-12-01 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이를 포함한 조성물 |
| EP3318265B1 (en) | 2015-07-02 | 2021-08-18 | Gemvax & Kael Co., Ltd. | Peptide having anti-viral effect and composition containing same |
| CN105018499A (zh) * | 2015-08-25 | 2015-11-04 | 武汉大学 | 一种抗乙型肝炎病毒的肽核酸及其用途 |
| CN108431021B (zh) * | 2015-11-03 | 2021-09-07 | 珍白斯凯尔有限公司 | 具有神经元损失预防和再生效果的肽以及包含该肽的组合物 |
| EP4272829A3 (en) | 2016-04-07 | 2024-01-17 | Gemvax & Kael Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
| WO2017180535A1 (en) * | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| CN106236695A (zh) * | 2016-06-02 | 2016-12-21 | 哈尔滨源茂达生物技术有限公司 | 一种多肽祛痘修复精华液及其制备方法 |
| TW201809013A (zh) | 2016-06-06 | 2018-03-16 | 艾斯克立必恩股份有限公司 | 用於藥物遞送之抗體融合蛋白 |
| KR101797167B1 (ko) * | 2016-11-09 | 2017-11-13 | 주식회사 바이오셀트란 | 신규의 프로테인 트랜스덕션 도메인 및 이의 용도 |
| CN107759698A (zh) * | 2017-09-18 | 2018-03-06 | 广东工业大学 | 一种egfp‑cta2‑tat融合蛋白在制备荧光探针中的应用 |
| CA3078504A1 (en) | 2017-10-04 | 2019-04-11 | Ohio State Innovation Foundation | Bicyclic peptidyl inhibitors |
| CN117567639A (zh) | 2017-10-27 | 2024-02-20 | 俄亥俄州国家创新基金会 | 用于细胞内递送装订肽的多肽缀合物 |
| WO2019148195A2 (en) | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Cyclic peptidyl inhibitors of cal-pdz binding domain |
| US11987647B2 (en) | 2018-05-09 | 2024-05-21 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
| CN109553659B (zh) * | 2018-11-26 | 2022-06-21 | 上海华新生物高技术有限公司 | 一种细胞穿透肽及透皮干扰素 |
| WO2020130547A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 엘알알씨24 단백질 유래 세포막 투과 도메인 |
| KR102351041B1 (ko) * | 2018-12-19 | 2022-01-13 | 한국화학연구원 | 인간 lrrc24 단백질 유래 세포막 투과 도메인 |
| KR102182985B1 (ko) * | 2019-01-03 | 2020-11-26 | 주식회사 바이오이즈 | pH 의존적 막 투과성 펩타이드를 이용한 약물 운반체 및 그것과 약물의 복합체 |
| US20220088213A1 (en) * | 2019-01-03 | 2022-03-24 | Sung Chun Kim | Drug delivery system using ph-dependent cell-penetrating peptides, and composite thereof with drug |
| EP3955967A4 (en) | 2019-04-17 | 2023-06-07 | Aadigen, LLC | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF MOLECULES |
| EP4058032A4 (en) * | 2019-12-19 | 2024-01-10 | Entrada Therapeutics, Inc. | Compositions for delivery of antisense compounds |
| WO2022012539A1 (zh) * | 2020-07-17 | 2022-01-20 | 养生堂有限公司 | 一种细胞穿膜肽及其应用 |
| US20230279143A1 (en) * | 2020-08-13 | 2023-09-07 | Nibec Co., Ltd. | Protein comprising antibody for targeting oncogenic protein or single chain fragment variable thereof and cancer cell penetrating peptide, and use of the same |
| CN114731988B (zh) * | 2022-05-23 | 2023-10-20 | 昆明市第一人民医院 | 一种hbv感染的树鼩模型构建方法及树鼩模型 |
| WO2025184403A2 (en) * | 2024-02-29 | 2025-09-04 | Memorial Sloan-Kettering Cancer Center | Cell penetrating peptides and methods including the same |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU207799B (en) | 1991-07-24 | 1993-06-28 | Beres Export Import Rt | Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis |
| US5885782A (en) * | 1994-09-13 | 1999-03-23 | Nce Pharmaceuticals, Inc. | Synthetic antibiotics |
| EP1806131A3 (en) | 1996-07-22 | 2007-08-01 | Renovo Limited | Use of sex steroid function modulators to treat wounds and fibrotic disorders |
| US6610839B1 (en) | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| KR100508338B1 (ko) | 1997-05-15 | 2005-08-17 | 츄가이 세이야꾸 가부시키가이샤 | 악액질 치료제 |
| KR100581990B1 (ko) | 1997-07-01 | 2006-05-23 | 캄비아 바이오시스템즈 엘엘씨 | 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도 |
| US6639057B1 (en) * | 1998-03-26 | 2003-10-28 | Kyowa Hakko Kogyo Co., Ltd. | Monoclonal antibody against human telomerase catalytic subunit |
| US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
| US7078491B1 (en) * | 2000-09-21 | 2006-07-18 | Amgen Inc. | Selective binding agents of telomerase |
| US6815426B2 (en) | 2001-02-16 | 2004-11-09 | E. I. Du Pont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| WO2002087578A1 (fr) | 2001-04-10 | 2002-11-07 | Nippon Shinyaku Co., Ltd. | Agent therapeutique pour rhumatisme articulaire chronique |
| EP1425028B1 (en) | 2001-05-16 | 2009-12-16 | Yeda Research And Development Co. Ltd. | Use of il-18 inhibitors for the treatement or prevention of sepsis |
| AU2002363231A1 (en) | 2001-10-29 | 2003-05-12 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen |
| US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| EP1515743A2 (en) | 2002-04-10 | 2005-03-23 | Applied Research Systems ARS Holding N.V. | Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| KR20050020987A (ko) | 2002-06-12 | 2005-03-04 | 바이오겐 아이덱 엠에이 인코포레이티드 | 아데노신 수용체 길항제를 사용하여 허혈 재관류 손상을치료하는 방법 |
| WO2005000227A2 (en) | 2003-06-06 | 2005-01-06 | Intermune, Inc. | Methods of treating tnf-mediated disorders |
| US7479484B2 (en) | 2003-06-25 | 2009-01-20 | Takeda Pharmaceutical Company Limited | Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity |
| KR20050040517A (ko) | 2003-10-29 | 2005-05-03 | 주식회사 오리엔트 | 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐 |
| ATE319426T1 (de) | 2003-11-11 | 2006-03-15 | Mattern Udo | Nasenformulierung mit kontrollierter freisetzung von sexualhormonen |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| WO2006102476A2 (en) | 2005-03-21 | 2006-09-28 | Vicus Therapeutics Spe 1, Llc | Compositions and methods for ameliorating cachexia |
| TW200803894A (en) | 2005-11-25 | 2008-01-16 | Univ Keio | Prostate cancer therapeutic agents |
| AU2006325030B2 (en) | 2005-12-16 | 2012-07-26 | Cellectis | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
| KR100859972B1 (ko) * | 2006-02-20 | 2008-09-25 | 이화여자대학교 산학협력단 | 막투과 단백질 도메인 펩타이드 |
| CN101490080A (zh) | 2006-07-24 | 2009-07-22 | 为人技术株式会社 | 用于缓解和治疗缺血性病症的药物组合物及其输送方法 |
| EP2837636B1 (en) | 2007-01-29 | 2018-04-11 | Procell Therapeutics Inc. | Novel macromolecule transduction domains and methods for identification and uses thereof |
| US8664358B2 (en) | 2007-06-29 | 2014-03-04 | Vermillion, Inc. | Predictive markers for ovarian cancer |
| JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| US8362209B2 (en) | 2007-08-23 | 2013-01-29 | University Of Medicine And Dentistry Of New Jersey | Telomerase reverse transcriptase variant |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| GB2455539B (en) | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| PL2310044T3 (pl) | 2008-06-16 | 2017-04-28 | Mediolanum Farmaceutici S.P.A. | Immunoterapia przeciwnowotworowa |
| US8252282B2 (en) | 2008-06-19 | 2012-08-28 | University Of Medicine & Dentistry Of New Jersey | Nuclear telomerase reverse transcriptase variant |
| ES2334315B1 (es) | 2008-07-29 | 2011-02-28 | Universitat Pompeu Fabra | Peptidos con capacidad de penetracion celular y sus usos. |
| TW201020245A (en) | 2008-08-20 | 2010-06-01 | Schering Corp | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| US20110183925A1 (en) | 2008-09-22 | 2011-07-28 | Nisshin Pharma Inc. | Anti-inflammatory peptide |
| EP2337795A2 (en) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| KR101169030B1 (ko) * | 2009-01-21 | 2012-07-26 | 애니젠 주식회사 | 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 |
| KR101237927B1 (ko) | 2009-05-07 | 2013-03-04 | (주)문엔제이 | 신경손상 및 신경질환 예방 또는 치료용 약학조성물 |
| EP2251028A1 (en) | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
| US7928067B2 (en) | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| RU2548807C2 (ru) * | 2009-05-20 | 2015-04-20 | Торэй Индастриз, Инк. | Пептиды, проникающие в клетку |
| KR20110057049A (ko) | 2009-11-23 | 2011-05-31 | 박의신 | 기능성 전립선염 치료제 |
| KR20110062943A (ko) | 2009-12-04 | 2011-06-10 | 주식회사종근당 | 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제 |
| JP6027893B2 (ja) | 2010-01-11 | 2016-11-16 | カッパーアールエヌエー，インコーポレイテッド | 性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療 |
| PL2536830T3 (pl) | 2010-02-16 | 2020-02-28 | Ultimovacs As | Polipeptydy |
| FR2960542B1 (fr) | 2010-05-27 | 2012-08-17 | Esther Suzy Arlette Fellous | Peptide en tant que medicament, en particulier pour le traitement du cancer |
| KR101263212B1 (ko) | 2010-05-28 | 2013-05-10 | 성신여자대학교 산학협력단 | 신규한 세포막 투과성 펩타이드 및 그의 용도 |
| WO2011150494A1 (en) | 2010-05-30 | 2011-12-08 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for anticancer compounds |
| WO2011155803A2 (ko) | 2010-06-11 | 2011-12-15 | 아주대학교산학협력단 | 청각보호 작용을 하는 신규 화합물 |
| KR101348284B1 (ko) * | 2010-09-09 | 2014-01-03 | 주식회사 나이벡 | 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| KR20120121196A (ko) | 2011-04-26 | 2012-11-05 | 주식회사 글루칸 | 관절염 치료제 |
| KR101284772B1 (ko) | 2011-05-24 | 2013-07-17 | 정종문 | 항염증, 진통효과를 가지는 기능성 식품 조성물 |
| KR20120133661A (ko) | 2011-05-31 | 2012-12-11 | 주식회사 바이오포트코리아 | 아스타잔틴을 포함하는 항염증제 |
| KR101288053B1 (ko) | 2011-07-04 | 2013-07-23 | 동국대학교 산학협력단 | 필발 추출물을 유효성분으로 포함하는 내이손상 예방 및 치료용 조성물 |
| KR101361445B1 (ko) | 2011-12-26 | 2014-02-12 | 성균관대학교산학협력단 | 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물 |
| DE13746292T1 (de) | 2012-02-10 | 2014-10-30 | Hakushinkouseikai Foundation | Proliferationsmittel für monozyten, kulturmedium zur proliferation von monozyten, verfahren zur herstellung von monozyten, verfahren zur herstellung dendritischer zellen und verfahren zur herstellung eines impfstoffs mit dendritischen zellen |
| WO2013135266A1 (en) | 2012-03-12 | 2013-09-19 | Gemvax As | Treatment of non-small cell lung carcinoma by active immunotherapy |
| WO2013169060A1 (ko) | 2012-05-11 | 2013-11-14 | 주식회사 카엘젬백스 | 패혈증 예방 또는 치료용 조성물 |
| ES2691070T3 (es) * | 2012-05-11 | 2018-11-23 | Kael-Gemvax Co.,Ltd | Péptidos antiinflamatorios y composición que comprende los mismos |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| KR102038487B1 (ko) | 2012-09-19 | 2019-10-30 | 주식회사 젬백스앤카엘 | 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물 |
| TWI678374B (zh) | 2012-09-19 | 2019-12-01 | 韓商傑姆維克斯＆凱爾有限公司 | 穿膜胜肽以及包含該胜肽之共軛物及組成物(三) |
| US9631184B2 (en) | 2012-09-19 | 2017-04-25 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| TWI616531B (zh) | 2012-09-19 | 2018-03-01 | 傑姆維克斯＆凱爾有限公司 | 穿膜胜肽以及包含該胜肽之共軛物及組成物（二） |
| KR20140104288A (ko) | 2013-02-20 | 2014-08-28 | 주식회사 카엘젬백스 | Tnf-알파 저해제 |
| AU2014218667A1 (en) | 2013-02-22 | 2015-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, compositions, methods, and kits relating to telomere extension |
| KR102258864B1 (ko) | 2013-04-19 | 2021-06-01 | 주식회사 젬백스앤카엘 | 허혈성 손상 치료 및 예방용 조성물 |
| RU2677277C2 (ru) | 2013-06-07 | 2019-01-16 | Джемвакс Энд Каэл Ко., Лтд. | Биологические маркеры, которые могут быть использованы в иммунотерапии рака |
| TWI539960B (zh) | 2013-06-21 | 2016-07-01 | 凱爾傑姆維克斯有限公司 | 激素分泌調節劑、包括其的組成物以及其用途 |
| CA2926183C (en) | 2013-10-23 | 2018-07-03 | Gemvax & Kael Co., Ltd. | Composition for treating and preventing benign prostatic hyperplasia |
| EP3072519B1 (en) | 2013-11-22 | 2020-08-19 | Gemvax & Kael Co., Ltd. | Peptide having angiogenesis inhibitory activity and composition containing same |
| ES2809251T3 (es) | 2013-12-17 | 2021-03-03 | Gemvax & Kael Co Ltd | Composición para tratar cáncer de próstata |
| JP6420459B2 (ja) | 2014-04-11 | 2018-11-07 | ジェムバックス アンド カエル カンパニー，リミティド | 線維症抑制活性を有するペプチド及びこれを含む組成物 |
| US10662223B2 (en) | 2014-04-30 | 2020-05-26 | Gemvax & Kael Co., Ltd. | Composition for organ, tissue, or cell transplantation, kit, and transplantation method |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| KR102636129B1 (ko) | 2015-02-27 | 2024-02-14 | 주식회사 젬백스앤카엘 | 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물 |
| CN108431021B (zh) | 2015-11-03 | 2021-09-07 | 珍白斯凯尔有限公司 | 具有神经元损失预防和再生效果的肽以及包含该肽的组合物 |
| KR20170054310A (ko) | 2015-11-09 | 2017-05-17 | 주식회사 젬백스앤카엘 | 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법 |
-
2013
- 2013-07-11 ES ES13816880T patent/ES2981865T3/es active Active
- 2013-07-11 US US14/413,732 patent/US10967000B2/en active Active
- 2013-07-11 WO PCT/KR2013/006218 patent/WO2014010971A1/ko not_active Ceased
- 2013-07-11 CN CN201380044357.3A patent/CN104822698B/zh active Active
- 2013-07-11 JP JP2015521549A patent/JP6272853B2/ja active Active
- 2013-07-11 EP EP13816880.2A patent/EP2873678B8/en active Active
- 2013-07-11 KR KR1020157002484A patent/KR101799904B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015530358A5 (enExample) | ||
| Chen et al. | Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis | |
| Kunjiappan et al. | Surface receptor‐mediated targeted drug delivery systems for enhanced cancer treatment: A state‐of‐the‐art review | |
| He et al. | Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer | |
| Nam et al. | Recent advances in selective and targeted drug/gene delivery systems using cell-penetrating peptides | |
| JP2016500648A5 (enExample) | ||
| Tian et al. | JQ1-loaded polydopamine nanoplatform inhibits c-MYC/programmed cell death ligand 1 to enhance photothermal therapy for triple-negative breast cancer | |
| JP2015530404A5 (enExample) | ||
| Ruan et al. | Stapled RGD peptide enables glioma-targeted drug delivery by overcoming multiple barriers | |
| Kondapi | Targeting cancer with lactoferrin nanoparticles: recent advances | |
| Zhao et al. | Degradable polymeric nanocapsule for efficient intracellular delivery of a high molecular weight tumor-selective protein complex | |
| Stuckey et al. | TRAIL on trial: preclinical advances in cancer therapy | |
| Chittasupho et al. | Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles | |
| JP2016500513A5 (enExample) | ||
| Kang et al. | A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma | |
| Li et al. | Targeting cancer gene therapy with magnetic nanoparticles | |
| US20120283316A1 (en) | Delivery of Therapeutic Agents Using Oligonucleotide-Modified Nanoparticles As Carriers | |
| Timur et al. | The role of peptide-based therapeutics in oncotherapy | |
| Bian et al. | Awakening p53 in vivo by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery | |
| Sorolla et al. | Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment | |
| Mehrotra et al. | Peptide-based combination nanoformulations for cancer therapy | |
| He et al. | A novel progress of drug delivery system for organelle targeting in tumour cells | |
| Kong et al. | Progress in tumour-targeted drug delivery based on cell-penetrating peptides | |
| AU2018273958A1 (en) | PD-1 and CTLA-4 dual inhibitor peptides | |
| WO2015135597A1 (en) | Uses and methods for delivery to the nucleus |